nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP3A7—Tamoxifen—pancreatic cancer	0.0503	0.0752	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0503	0.0752	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0386	0.0577	CbGbCtD
Nefazodone—CYP3A7—Irinotecan—pancreatic cancer	0.0386	0.0577	CbGbCtD
Nefazodone—CYP3A5—Tamoxifen—pancreatic cancer	0.0377	0.0564	CbGbCtD
Nefazodone—CYP3A5—Erlotinib—pancreatic cancer	0.0321	0.048	CbGbCtD
Nefazodone—CYP3A5—Irinotecan—pancreatic cancer	0.029	0.0433	CbGbCtD
Nefazodone—CYP3A7—Docetaxel—pancreatic cancer	0.0283	0.0423	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0283	0.0423	CbGbCtD
Nefazodone—CYP3A7—Sunitinib—pancreatic cancer	0.0282	0.0421	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.0282	0.0421	CbGbCtD
Nefazodone—ABCB1—Tamoxifen—pancreatic cancer	0.0246	0.0367	CbGbCtD
Nefazodone—CYP2D6—Tamoxifen—pancreatic cancer	0.0231	0.0346	CbGbCtD
Nefazodone—CYP3A5—Docetaxel—pancreatic cancer	0.0212	0.0317	CbGbCtD
Nefazodone—ABCB1—Gemcitabine—pancreatic cancer	0.0212	0.0316	CbGbCtD
Nefazodone—CYP3A5—Sunitinib—pancreatic cancer	0.0211	0.0316	CbGbCtD
Nefazodone—ABCB1—Erlotinib—pancreatic cancer	0.0209	0.0312	CbGbCtD
Nefazodone—CYP2D6—Erlotinib—pancreatic cancer	0.0197	0.0294	CbGbCtD
Nefazodone—ABCB1—Irinotecan—pancreatic cancer	0.0189	0.0282	CbGbCtD
Nefazodone—CYP3A4—Tamoxifen—pancreatic cancer	0.0147	0.022	CbGbCtD
Nefazodone—ABCB1—Docetaxel—pancreatic cancer	0.0138	0.0207	CbGbCtD
Nefazodone—ABCB1—Sunitinib—pancreatic cancer	0.0138	0.0206	CbGbCtD
Nefazodone—CYP3A4—Erlotinib—pancreatic cancer	0.0125	0.0187	CbGbCtD
Nefazodone—CYP3A4—Irinotecan—pancreatic cancer	0.0113	0.0169	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—pancreatic cancer	0.0103	0.0154	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—pancreatic cancer	0.00971	0.0145	CbGbCtD
Nefazodone—CYP3A4—Docetaxel—pancreatic cancer	0.00828	0.0124	CbGbCtD
Nefazodone—CYP3A4—Sunitinib—pancreatic cancer	0.00824	0.0123	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—pancreatic cancer	0.00617	0.00923	CbGbCtD
Nefazodone—Rash—Sunitinib—pancreatic cancer	0.000165	0.000654	CcSEcCtD
Nefazodone—Dermatitis—Sunitinib—pancreatic cancer	0.000165	0.000654	CcSEcCtD
Nefazodone—Abdominal distension—Doxorubicin—pancreatic cancer	0.000165	0.000653	CcSEcCtD
Nefazodone—Urticaria—Fluorouracil—pancreatic cancer	0.000164	0.00065	CcSEcCtD
Nefazodone—Headache—Sunitinib—pancreatic cancer	0.000164	0.00065	CcSEcCtD
Nefazodone—Syncope—Docetaxel—pancreatic cancer	0.000164	0.000649	CcSEcCtD
Nefazodone—Asthma—Doxorubicin—pancreatic cancer	0.000164	0.000649	CcSEcCtD
Nefazodone—Influenza—Doxorubicin—pancreatic cancer	0.000164	0.000649	CcSEcCtD
Nefazodone—Dysphagia—Doxorubicin—pancreatic cancer	0.000164	0.000649	CcSEcCtD
Nefazodone—Leukopenia—Docetaxel—pancreatic cancer	0.000163	0.000648	CcSEcCtD
Nefazodone—Pollakiuria—Epirubicin—pancreatic cancer	0.000163	0.000648	CcSEcCtD
Nefazodone—Body temperature increased—Fluorouracil—pancreatic cancer	0.000163	0.000647	CcSEcCtD
Nefazodone—Palpitations—Docetaxel—pancreatic cancer	0.000161	0.00064	CcSEcCtD
Nefazodone—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000161	0.00064	CcSEcCtD
Nefazodone—Weight increased—Epirubicin—pancreatic cancer	0.000161	0.000638	CcSEcCtD
Nefazodone—Loss of consciousness—Docetaxel—pancreatic cancer	0.000161	0.000636	CcSEcCtD
Nefazodone—Weight decreased—Epirubicin—pancreatic cancer	0.00016	0.000634	CcSEcCtD
Nefazodone—Cough—Docetaxel—pancreatic cancer	0.000159	0.000632	CcSEcCtD
Nefazodone—Angina pectoris—Doxorubicin—pancreatic cancer	0.000159	0.000632	CcSEcCtD
Nefazodone—Hypersensitivity—Irinotecan—pancreatic cancer	0.000159	0.00063	CcSEcCtD
Nefazodone—Pneumonia—Epirubicin—pancreatic cancer	0.000159	0.000629	CcSEcCtD
Nefazodone—Convulsion—Docetaxel—pancreatic cancer	0.000158	0.000627	CcSEcCtD
Nefazodone—Hypertension—Docetaxel—pancreatic cancer	0.000158	0.000625	CcSEcCtD
Nefazodone—Bronchitis—Doxorubicin—pancreatic cancer	0.000157	0.000624	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000156	0.00062	CcSEcCtD
Nefazodone—Chest pain—Docetaxel—pancreatic cancer	0.000156	0.000616	CcSEcCtD
Nefazodone—Arthralgia—Docetaxel—pancreatic cancer	0.000156	0.000616	CcSEcCtD
Nefazodone—Myalgia—Docetaxel—pancreatic cancer	0.000156	0.000616	CcSEcCtD
Nefazodone—Nausea—Sunitinib—pancreatic cancer	0.000156	0.000616	CcSEcCtD
Nefazodone—Asthenia—Irinotecan—pancreatic cancer	0.000155	0.000613	CcSEcCtD
Nefazodone—Stomatitis—Epirubicin—pancreatic cancer	0.000154	0.000609	CcSEcCtD
Nefazodone—Urinary tract infection—Epirubicin—pancreatic cancer	0.000153	0.000607	CcSEcCtD
Nefazodone—Conjunctivitis—Epirubicin—pancreatic cancer	0.000153	0.000607	CcSEcCtD
Nefazodone—Dysuria—Doxorubicin—pancreatic cancer	0.000153	0.000606	CcSEcCtD
Nefazodone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000152	0.000603	CcSEcCtD
Nefazodone—Dry mouth—Docetaxel—pancreatic cancer	0.000152	0.000603	CcSEcCtD
Nefazodone—Sweating—Epirubicin—pancreatic cancer	0.000151	0.000599	CcSEcCtD
Nefazodone—Pollakiuria—Doxorubicin—pancreatic cancer	0.000151	0.000599	CcSEcCtD
Nefazodone—Asthenia—Gemcitabine—pancreatic cancer	0.000151	0.000597	CcSEcCtD
Nefazodone—Haematuria—Epirubicin—pancreatic cancer	0.00015	0.000596	CcSEcCtD
Nefazodone—Confusional state—Docetaxel—pancreatic cancer	0.00015	0.000596	CcSEcCtD
Nefazodone—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000149	0.000592	CcSEcCtD
Nefazodone—Oedema—Docetaxel—pancreatic cancer	0.000149	0.000591	CcSEcCtD
Nefazodone—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000149	0.000591	CcSEcCtD
Nefazodone—Weight increased—Doxorubicin—pancreatic cancer	0.000149	0.00059	CcSEcCtD
Nefazodone—Epistaxis—Epirubicin—pancreatic cancer	0.000149	0.000589	CcSEcCtD
Nefazodone—Pruritus—Gemcitabine—pancreatic cancer	0.000149	0.000589	CcSEcCtD
Nefazodone—Infection—Docetaxel—pancreatic cancer	0.000148	0.000587	CcSEcCtD
Nefazodone—Weight decreased—Doxorubicin—pancreatic cancer	0.000148	0.000587	CcSEcCtD
Nefazodone—Sinusitis—Epirubicin—pancreatic cancer	0.000148	0.000586	CcSEcCtD
Nefazodone—Diarrhoea—Irinotecan—pancreatic cancer	0.000148	0.000585	CcSEcCtD
Nefazodone—Pneumonia—Doxorubicin—pancreatic cancer	0.000147	0.000582	CcSEcCtD
Nefazodone—Shock—Docetaxel—pancreatic cancer	0.000147	0.000581	CcSEcCtD
Nefazodone—Pruritus—Fluorouracil—pancreatic cancer	0.000146	0.000579	CcSEcCtD
Nefazodone—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000146	0.000579	CcSEcCtD
Nefazodone—Tachycardia—Docetaxel—pancreatic cancer	0.000145	0.000577	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000145	0.000573	CcSEcCtD
Nefazodone—Bradycardia—Epirubicin—pancreatic cancer	0.000144	0.000571	CcSEcCtD
Nefazodone—Diarrhoea—Gemcitabine—pancreatic cancer	0.000144	0.00057	CcSEcCtD
Nefazodone—Dizziness—Irinotecan—pancreatic cancer	0.000143	0.000565	CcSEcCtD
Nefazodone—Haemoglobin—Epirubicin—pancreatic cancer	0.000142	0.000564	CcSEcCtD
Nefazodone—Stomatitis—Doxorubicin—pancreatic cancer	0.000142	0.000564	CcSEcCtD
Nefazodone—Anorexia—Docetaxel—pancreatic cancer	0.000142	0.000563	CcSEcCtD
Nefazodone—Rhinitis—Epirubicin—pancreatic cancer	0.000142	0.000562	CcSEcCtD
Nefazodone—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000142	0.000562	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000142	0.000562	CcSEcCtD
Nefazodone—Hepatitis—Epirubicin—pancreatic cancer	0.000142	0.000561	CcSEcCtD
Nefazodone—Haemorrhage—Epirubicin—pancreatic cancer	0.000142	0.000561	CcSEcCtD
Nefazodone—Diarrhoea—Fluorouracil—pancreatic cancer	0.000141	0.00056	CcSEcCtD
Nefazodone—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000141	0.000558	CcSEcCtD
Nefazodone—Pharyngitis—Epirubicin—pancreatic cancer	0.00014	0.000557	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—pancreatic cancer	0.00014	0.000554	CcSEcCtD
Nefazodone—Oedema peripheral—Epirubicin—pancreatic cancer	0.000139	0.000553	CcSEcCtD
Nefazodone—Hypotension—Docetaxel—pancreatic cancer	0.000139	0.000552	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—pancreatic cancer	0.000139	0.000551	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—pancreatic cancer	0.000138	0.000545	CcSEcCtD
Nefazodone—Vomiting—Irinotecan—pancreatic cancer	0.000137	0.000544	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—pancreatic cancer	0.000137	0.000543	CcSEcCtD
Nefazodone—Dizziness—Fluorouracil—pancreatic cancer	0.000137	0.000541	CcSEcCtD
Nefazodone—Visual impairment—Epirubicin—pancreatic cancer	0.000136	0.000541	CcSEcCtD
Nefazodone—Rash—Irinotecan—pancreatic cancer	0.000136	0.000539	CcSEcCtD
Nefazodone—Dermatitis—Irinotecan—pancreatic cancer	0.000136	0.000539	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000136	0.000538	CcSEcCtD
Nefazodone—Headache—Irinotecan—pancreatic cancer	0.000135	0.000536	CcSEcCtD
Nefazodone—Insomnia—Docetaxel—pancreatic cancer	0.000135	0.000534	CcSEcCtD
Nefazodone—Paraesthesia—Docetaxel—pancreatic cancer	0.000134	0.000531	CcSEcCtD
Nefazodone—Erythema multiforme—Epirubicin—pancreatic cancer	0.000134	0.00053	CcSEcCtD
Nefazodone—Vomiting—Gemcitabine—pancreatic cancer	0.000134	0.000529	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—pancreatic cancer	0.000133	0.000528	CcSEcCtD
Nefazodone—Dyspnoea—Docetaxel—pancreatic cancer	0.000133	0.000527	CcSEcCtD
Nefazodone—Somnolence—Docetaxel—pancreatic cancer	0.000133	0.000525	CcSEcCtD
Nefazodone—Rash—Gemcitabine—pancreatic cancer	0.000132	0.000525	CcSEcCtD
Nefazodone—Dermatitis—Gemcitabine—pancreatic cancer	0.000132	0.000525	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—pancreatic cancer	0.000132	0.000523	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—pancreatic cancer	0.000132	0.000522	CcSEcCtD
Nefazodone—Headache—Gemcitabine—pancreatic cancer	0.000132	0.000522	CcSEcCtD
Nefazodone—Flushing—Epirubicin—pancreatic cancer	0.000131	0.000521	CcSEcCtD
Nefazodone—Vomiting—Fluorouracil—pancreatic cancer	0.000131	0.000521	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—pancreatic cancer	0.000131	0.00052	CcSEcCtD
Nefazodone—Dyspepsia—Docetaxel—pancreatic cancer	0.000131	0.00052	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—pancreatic cancer	0.000131	0.000519	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—pancreatic cancer	0.000131	0.000519	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.00013	0.000517	CcSEcCtD
Nefazodone—Rash—Fluorouracil—pancreatic cancer	0.00013	0.000516	CcSEcCtD
Nefazodone—Dermatitis—Fluorouracil—pancreatic cancer	0.00013	0.000516	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—pancreatic cancer	0.00013	0.000515	CcSEcCtD
Nefazodone—Decreased appetite—Docetaxel—pancreatic cancer	0.00013	0.000514	CcSEcCtD
Nefazodone—Headache—Fluorouracil—pancreatic cancer	0.000129	0.000513	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000129	0.000511	CcSEcCtD
Nefazodone—Nausea—Irinotecan—pancreatic cancer	0.000128	0.000508	CcSEcCtD
Nefazodone—Pain—Docetaxel—pancreatic cancer	0.000127	0.000505	CcSEcCtD
Nefazodone—Constipation—Docetaxel—pancreatic cancer	0.000127	0.000505	CcSEcCtD
Nefazodone—Chills—Epirubicin—pancreatic cancer	0.000127	0.000503	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—pancreatic cancer	0.000126	0.0005	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—pancreatic cancer	0.000125	0.000496	CcSEcCtD
Nefazodone—Nausea—Gemcitabine—pancreatic cancer	0.000125	0.000495	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000124	0.000491	CcSEcCtD
Nefazodone—Feeling abnormal—Docetaxel—pancreatic cancer	0.000123	0.000487	CcSEcCtD
Nefazodone—Nausea—Fluorouracil—pancreatic cancer	0.000123	0.000486	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—pancreatic cancer	0.000122	0.000484	CcSEcCtD
Nefazodone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000122	0.000483	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—pancreatic cancer	0.000122	0.000482	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—pancreatic cancer	0.000121	0.000481	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—pancreatic cancer	0.000121	0.000478	CcSEcCtD
Nefazodone—Back pain—Epirubicin—pancreatic cancer	0.000119	0.000472	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—pancreatic cancer	0.000118	0.00047	CcSEcCtD
Nefazodone—Abdominal pain—Docetaxel—pancreatic cancer	0.000118	0.000467	CcSEcCtD
Nefazodone—Body temperature increased—Docetaxel—pancreatic cancer	0.000118	0.000467	CcSEcCtD
Nefazodone—Chills—Doxorubicin—pancreatic cancer	0.000117	0.000466	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—pancreatic cancer	0.000116	0.00046	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—pancreatic cancer	0.000116	0.000459	CcSEcCtD
Nefazodone—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000114	0.000453	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—pancreatic cancer	0.000114	0.000451	CcSEcCtD
Nefazodone—Agitation—Epirubicin—pancreatic cancer	0.000113	0.000449	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—pancreatic cancer	0.000112	0.000445	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—pancreatic cancer	0.000112	0.000443	CcSEcCtD
Nefazodone—Malaise—Epirubicin—pancreatic cancer	0.000111	0.00044	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—pancreatic cancer	0.000111	0.000439	CcSEcCtD
Nefazodone—Syncope—Epirubicin—pancreatic cancer	0.00011	0.000438	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—pancreatic cancer	0.00011	0.000437	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—pancreatic cancer	0.00011	0.000437	CcSEcCtD
Nefazodone—Hypersensitivity—Docetaxel—pancreatic cancer	0.00011	0.000435	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—pancreatic cancer	0.00011	0.000434	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—pancreatic cancer	0.000109	0.000432	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—pancreatic cancer	0.000108	0.000429	CcSEcCtD
Nefazodone—Cough—Epirubicin—pancreatic cancer	0.000108	0.000426	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—pancreatic cancer	0.000107	0.000426	CcSEcCtD
Nefazodone—Asthenia—Docetaxel—pancreatic cancer	0.000107	0.000424	CcSEcCtD
Nefazodone—Convulsion—Epirubicin—pancreatic cancer	0.000107	0.000423	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—pancreatic cancer	0.000106	0.000422	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000106	0.000419	CcSEcCtD
Nefazodone—Pruritus—Docetaxel—pancreatic cancer	0.000105	0.000418	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—pancreatic cancer	0.000105	0.000418	CcSEcCtD
Nefazodone—Arthralgia—Epirubicin—pancreatic cancer	0.000105	0.000416	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—pancreatic cancer	0.000105	0.000416	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—pancreatic cancer	0.000105	0.000416	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—pancreatic cancer	0.000105	0.000415	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—pancreatic cancer	0.000105	0.000414	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—pancreatic cancer	0.000104	0.000411	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—pancreatic cancer	0.000103	0.000408	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—pancreatic cancer	0.000103	0.000407	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—pancreatic cancer	0.000102	0.000406	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—pancreatic cancer	0.000102	0.000405	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—pancreatic cancer	0.000102	0.000405	CcSEcCtD
Nefazodone—Diarrhoea—Docetaxel—pancreatic cancer	0.000102	0.000404	CcSEcCtD
Nefazodone—Confusional state—Epirubicin—pancreatic cancer	0.000101	0.000402	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—pancreatic cancer	0.000101	0.000399	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000101	0.000399	CcSEcCtD
Nefazodone—Oedema—Epirubicin—pancreatic cancer	0.000101	0.000399	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—pancreatic cancer	0.0001	0.000397	CcSEcCtD
Nefazodone—Infection—Epirubicin—pancreatic cancer	9.99e-05	0.000396	CcSEcCtD
Nefazodone—Cough—Doxorubicin—pancreatic cancer	9.95e-05	0.000394	CcSEcCtD
Nefazodone—Shock—Epirubicin—pancreatic cancer	9.89e-05	0.000392	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—pancreatic cancer	9.88e-05	0.000392	CcSEcCtD
Nefazodone—Dizziness—Docetaxel—pancreatic cancer	9.86e-05	0.000391	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—pancreatic cancer	9.84e-05	0.00039	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—pancreatic cancer	9.84e-05	0.00039	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—pancreatic cancer	9.81e-05	0.000389	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—pancreatic cancer	9.72e-05	0.000385	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—pancreatic cancer	9.7e-05	0.000385	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—pancreatic cancer	9.7e-05	0.000385	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—pancreatic cancer	9.7e-05	0.000385	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—pancreatic cancer	9.67e-05	0.000383	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—pancreatic cancer	9.59e-05	0.00038	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—pancreatic cancer	9.58e-05	0.00038	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—pancreatic cancer	9.49e-05	0.000376	CcSEcCtD
Nefazodone—Vomiting—Docetaxel—pancreatic cancer	9.48e-05	0.000376	CcSEcCtD
Nefazodone—Rash—Docetaxel—pancreatic cancer	9.4e-05	0.000373	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—pancreatic cancer	9.4e-05	0.000372	CcSEcCtD
Nefazodone—Dermatitis—Docetaxel—pancreatic cancer	9.39e-05	0.000372	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—pancreatic cancer	9.38e-05	0.000372	CcSEcCtD
Nefazodone—Headache—Docetaxel—pancreatic cancer	9.34e-05	0.00037	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—pancreatic cancer	9.3e-05	0.000369	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—pancreatic cancer	9.3e-05	0.000369	CcSEcCtD
Nefazodone—Infection—Doxorubicin—pancreatic cancer	9.24e-05	0.000366	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	9.16e-05	0.000363	CcSEcCtD
Nefazodone—Shock—Doxorubicin—pancreatic cancer	9.15e-05	0.000363	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—pancreatic cancer	9.11e-05	0.000361	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—pancreatic cancer	9.09e-05	0.000361	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—pancreatic cancer	9.08e-05	0.00036	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—pancreatic cancer	9.03e-05	0.000358	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—pancreatic cancer	8.99e-05	0.000357	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—pancreatic cancer	8.96e-05	0.000355	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—pancreatic cancer	8.94e-05	0.000354	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—pancreatic cancer	8.87e-05	0.000352	CcSEcCtD
Nefazodone—Nausea—Docetaxel—pancreatic cancer	8.85e-05	0.000351	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—pancreatic cancer	8.85e-05	0.000351	CcSEcCtD
Nefazodone—Decreased appetite—Epirubicin—pancreatic cancer	8.74e-05	0.000346	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—pancreatic cancer	8.69e-05	0.000345	CcSEcCtD
Nefazodone—Constipation—Epirubicin—pancreatic cancer	8.6e-05	0.000341	CcSEcCtD
Nefazodone—Pain—Epirubicin—pancreatic cancer	8.6e-05	0.000341	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	8.48e-05	0.000336	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—pancreatic cancer	8.41e-05	0.000334	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—pancreatic cancer	8.35e-05	0.000331	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—pancreatic cancer	8.29e-05	0.000329	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—pancreatic cancer	8.29e-05	0.000328	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—pancreatic cancer	8.27e-05	0.000328	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—pancreatic cancer	8.22e-05	0.000326	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—pancreatic cancer	8.19e-05	0.000325	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—pancreatic cancer	8.09e-05	0.000321	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—pancreatic cancer	7.99e-05	0.000317	CcSEcCtD
Nefazodone—Pain—Doxorubicin—pancreatic cancer	7.96e-05	0.000315	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—pancreatic cancer	7.96e-05	0.000315	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—pancreatic cancer	7.95e-05	0.000315	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—pancreatic cancer	7.95e-05	0.000315	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—pancreatic cancer	7.67e-05	0.000304	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	7.61e-05	0.000302	CcSEcCtD
Nefazodone—Hypersensitivity—Epirubicin—pancreatic cancer	7.41e-05	0.000294	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—pancreatic cancer	7.39e-05	0.000293	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—pancreatic cancer	7.35e-05	0.000292	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—pancreatic cancer	7.35e-05	0.000292	CcSEcCtD
Nefazodone—Asthenia—Epirubicin—pancreatic cancer	7.21e-05	0.000286	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—pancreatic cancer	7.11e-05	0.000282	CcSEcCtD
Nefazodone—Diarrhoea—Epirubicin—pancreatic cancer	6.88e-05	0.000273	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—pancreatic cancer	6.85e-05	0.000272	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—pancreatic cancer	6.67e-05	0.000265	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—pancreatic cancer	6.65e-05	0.000264	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—pancreatic cancer	6.58e-05	0.000261	CcSEcCtD
Nefazodone—Vomiting—Epirubicin—pancreatic cancer	6.39e-05	0.000253	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—pancreatic cancer	6.37e-05	0.000252	CcSEcCtD
Nefazodone—Rash—Epirubicin—pancreatic cancer	6.34e-05	0.000251	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—pancreatic cancer	6.33e-05	0.000251	CcSEcCtD
Nefazodone—Headache—Epirubicin—pancreatic cancer	6.3e-05	0.00025	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—pancreatic cancer	6.15e-05	0.000244	CcSEcCtD
Nefazodone—Nausea—Epirubicin—pancreatic cancer	5.97e-05	0.000237	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—pancreatic cancer	5.92e-05	0.000234	CcSEcCtD
Nefazodone—Rash—Doxorubicin—pancreatic cancer	5.87e-05	0.000233	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—pancreatic cancer	5.86e-05	0.000232	CcSEcCtD
Nefazodone—Headache—Doxorubicin—pancreatic cancer	5.83e-05	0.000231	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—pancreatic cancer	5.53e-05	0.000219	CcSEcCtD
Nefazodone—CYP2D6—Metabolism—STK11—pancreatic cancer	9.56e-06	0.000122	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HIF1A—pancreatic cancer	9.47e-06	0.000121	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TSC2—pancreatic cancer	9.44e-06	0.00012	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—DPYD—pancreatic cancer	9.44e-06	0.00012	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APOE—pancreatic cancer	9.44e-06	0.00012	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—APOE—pancreatic cancer	9.41e-06	0.00012	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CG—pancreatic cancer	9.39e-06	0.00012	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—NRAS—pancreatic cancer	9.39e-06	0.00012	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGF—pancreatic cancer	9.28e-06	0.000118	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	9.27e-06	0.000118	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KDR—pancreatic cancer	9.25e-06	0.000118	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	9.24e-06	0.000118	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	9.2e-06	0.000117	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	9.05e-06	0.000115	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	9e-06	0.000115	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—pancreatic cancer	8.98e-06	0.000114	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	8.96e-06	0.000114	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PPARG—pancreatic cancer	8.94e-06	0.000114	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—pancreatic cancer	8.94e-06	0.000114	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—pancreatic cancer	8.92e-06	0.000114	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	8.79e-06	0.000112	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NFKBIA—pancreatic cancer	8.79e-06	0.000112	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	8.77e-06	0.000112	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TYMS—pancreatic cancer	8.73e-06	0.000111	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—AKT1—pancreatic cancer	8.72e-06	0.000111	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	8.71e-06	0.000111	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	8.67e-06	0.00011	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	8.62e-06	0.00011	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	8.61e-06	0.00011	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	8.59e-06	0.000109	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.58e-06	0.000109	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—pancreatic cancer	8.55e-06	0.000109	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.54e-06	0.000109	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	8.53e-06	0.000109	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	8.52e-06	0.000108	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	8.52e-06	0.000108	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	8.49e-06	0.000108	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	8.48e-06	0.000108	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	8.44e-06	0.000108	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGF—pancreatic cancer	8.42e-06	0.000107	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	8.41e-06	0.000107	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	8.34e-06	0.000106	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	8.34e-06	0.000106	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CD—pancreatic cancer	8.25e-06	0.000105	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	8.24e-06	0.000105	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TYMS—pancreatic cancer	8.23e-06	0.000105	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—pancreatic cancer	8.2e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.17e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	8.15e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—KRAS—pancreatic cancer	8.08e-06	0.000103	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	8e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	7.92e-06	0.000101	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	7.8e-06	9.93e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTEN—pancreatic cancer	7.78e-06	9.91e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	7.76e-06	9.88e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	7.76e-06	9.88e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	7.75e-06	9.87e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	7.75e-06	9.87e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	7.66e-06	9.76e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	7.6e-06	9.68e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	7.55e-06	9.62e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	7.52e-06	9.57e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	7.49e-06	9.54e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	7.46e-06	9.51e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PIK3CA—pancreatic cancer	7.42e-06	9.46e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.42e-06	9.45e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	7.33e-06	9.34e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	7.33e-06	9.34e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.26e-06	9.25e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	7.26e-06	9.25e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	7.22e-06	9.2e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	7.21e-06	9.19e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	7.19e-06	9.16e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	7.18e-06	9.14e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	7.17e-06	9.14e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	7.1e-06	9.04e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOE—pancreatic cancer	7.1e-06	9.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	7.06e-06	8.99e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—pancreatic cancer	7.04e-06	8.96e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	7.01e-06	8.93e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	6.98e-06	8.89e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	6.95e-06	8.85e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CD44—pancreatic cancer	6.94e-06	8.84e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	6.91e-06	8.81e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	6.91e-06	8.8e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	6.87e-06	8.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	6.81e-06	8.68e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	6.76e-06	8.61e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.75e-06	8.59e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.73e-06	8.58e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	6.73e-06	8.57e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	6.7e-06	8.53e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOE—pancreatic cancer	6.69e-06	8.52e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	6.68e-06	8.51e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	6.67e-06	8.49e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	6.66e-06	8.49e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GCG—pancreatic cancer	6.65e-06	8.47e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	6.62e-06	8.43e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.59e-06	8.4e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	6.57e-06	8.36e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	6.53e-06	8.32e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	6.53e-06	8.32e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	6.53e-06	8.31e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	6.51e-06	8.29e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	6.49e-06	8.27e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—pancreatic cancer	6.45e-06	8.21e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	6.44e-06	8.2e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CG—pancreatic cancer	6.41e-06	8.16e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	6.39e-06	8.14e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	6.38e-06	8.12e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	6.37e-06	8.11e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	6.34e-06	8.07e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	6.27e-06	7.99e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	6.25e-06	7.97e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—STK11—pancreatic cancer	6.25e-06	7.97e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	6.23e-06	7.94e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	6.22e-06	7.92e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—pancreatic cancer	6.18e-06	7.88e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	6.14e-06	7.82e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—pancreatic cancer	6.14e-06	7.82e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.13e-06	7.8e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	6.1e-06	7.77e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	6.06e-06	7.73e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	6.06e-06	7.72e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SRC—pancreatic cancer	6.05e-06	7.71e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	6.04e-06	7.69e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SRC—pancreatic cancer	6.02e-06	7.67e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	6e-06	7.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	5.94e-06	7.56e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	5.93e-06	7.56e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	5.9e-06	7.51e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	5.88e-06	7.49e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	5.87e-06	7.47e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	5.84e-06	7.44e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	5.84e-06	7.44e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—pancreatic cancer	5.83e-06	7.42e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	5.82e-06	7.42e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	5.81e-06	7.4e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	5.79e-06	7.38e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	5.79e-06	7.37e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	5.76e-06	7.34e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	5.72e-06	7.29e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	5.71e-06	7.27e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	5.67e-06	7.23e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	5.67e-06	7.22e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	5.67e-06	7.22e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	5.64e-06	7.18e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CD—pancreatic cancer	5.63e-06	7.18e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—pancreatic cancer	5.62e-06	7.16e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	5.61e-06	7.15e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	5.56e-06	7.08e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	5.55e-06	7.08e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	5.55e-06	7.06e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	5.52e-06	7.03e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	5.51e-06	7.02e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	5.5e-06	7.01e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	5.49e-06	6.99e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	5.46e-06	6.96e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—pancreatic cancer	5.42e-06	6.91e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	5.41e-06	6.89e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—pancreatic cancer	5.4e-06	6.87e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	5.39e-06	6.86e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	5.38e-06	6.86e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TYMS—pancreatic cancer	5.38e-06	6.85e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	5.32e-06	6.77e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	5.31e-06	6.76e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	5.31e-06	6.76e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	5.28e-06	6.72e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	5.26e-06	6.71e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SRC—pancreatic cancer	5.23e-06	6.66e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	5.17e-06	6.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	5.16e-06	6.57e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	5.15e-06	6.56e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	5.13e-06	6.54e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	5.12e-06	6.52e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	5.09e-06	6.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	5.05e-06	6.44e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	5.04e-06	6.42e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	5.03e-06	6.41e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	5.01e-06	6.38e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	5.01e-06	6.38e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	4.99e-06	6.35e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	4.99e-06	6.35e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	4.94e-06	6.29e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	4.93e-06	6.28e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.91e-06	6.25e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—pancreatic cancer	4.86e-06	6.2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	4.77e-06	6.08e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	4.76e-06	6.06e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—pancreatic cancer	4.69e-06	5.97e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	4.67e-06	5.96e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	4.63e-06	5.9e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	4.63e-06	5.89e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	4.6e-06	5.87e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	4.59e-06	5.85e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	4.59e-06	5.84e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—pancreatic cancer	4.58e-06	5.84e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	4.58e-06	5.84e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	4.58e-06	5.84e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	4.58e-06	5.83e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	4.58e-06	5.83e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	4.49e-06	5.72e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—pancreatic cancer	4.48e-06	5.71e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—pancreatic cancer	4.45e-06	5.67e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—pancreatic cancer	4.43e-06	5.65e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	4.39e-06	5.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOE—pancreatic cancer	4.37e-06	5.57e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	4.33e-06	5.52e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	4.33e-06	5.51e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	4.26e-06	5.43e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	4.26e-06	5.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	4.25e-06	5.42e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—pancreatic cancer	4.24e-06	5.4e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	4.24e-06	5.4e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	4.24e-06	5.4e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	4.24e-06	5.4e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	4.17e-06	5.31e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	4.06e-06	5.17e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—pancreatic cancer	4e-06	5.09e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	3.98e-06	5.07e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	3.97e-06	5.05e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.95e-06	5.03e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	3.94e-06	5.02e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	3.9e-06	4.96e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—pancreatic cancer	3.85e-06	4.9e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.81e-06	4.85e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	3.77e-06	4.8e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	3.76e-06	4.79e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	3.74e-06	4.77e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	3.68e-06	4.69e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	3.62e-06	4.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	3.6e-06	4.59e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	3.58e-06	4.56e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—pancreatic cancer	3.54e-06	4.5e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	3.5e-06	4.46e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	3.47e-06	4.42e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	3.35e-06	4.27e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	3.25e-06	4.14e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—pancreatic cancer	3.24e-06	4.13e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	3.18e-06	4.05e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	3.03e-06	3.85e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—pancreatic cancer	3e-06	3.82e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.99e-06	3.81e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	2.96e-06	3.77e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.82e-06	3.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.61e-06	3.33e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—pancreatic cancer	2.45e-06	3.11e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.3e-06	2.94e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.84e-06	2.35e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.51e-06	1.92e-05	CbGpPWpGaD
